No profile data available.
Bioventus Inc. (BVS) is a healthcare company in the bone and joint treatment equipment industry, based in Durham, United States, with about 950 full-time employees.
It reported revenue of $573.28 million for fiscal year 2024, up 11.9% from fiscal year 2023, and net income of -$33.54 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $138.65 million, down 0.2% from a year before. Its largest business segment, U.S. Segment, brought in 88% of segment revenue in fiscal year 2025; UNITED STATES was the largest region with 88%. Its market capitalization was $892.41 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Bioventus reported $573.28 million in revenue for fiscal year 2024, up 11.9% from $512.35 million in fiscal year 2023. In Q3 2025 revenue was $138.65 million.
U.S. Segment, with $502.10 million or 88% of segment revenue in fiscal year 2025. Next: International Segment (12%).
UNITED STATES: 88% of revenue by region in fiscal year 2025, followed by Non-US (12%).
$892.41 million as of October 9, 2026.
Listed companies of a similar size in the same industry (bone and joint treatment equipment) include Vericel Corporation (VCEL), Alphatec Holdings, Inc. (ATEC), Enovis Corporation (ENOV), Si-bone, Inc. (SIBN).